SAFETY DATA SHEET

MVP Total RNA - Human Adult Kidney - Disease Match Set, Part Number 540083

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name: MVP Total RNA - Human Adult Kidney - Disease Match Set, Part Number 540083
Part No. (Kit): 540083
Part No.: MVP Total RNA Human Adult Kidney 540013-41
MVP Total RNA, Human Adult Kidney 540081-41
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

1.2 Relevant identified uses of the substance or mixture and uses advised against

<table>
<thead>
<tr>
<th>Identified uses</th>
<th>25 µg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analytical reagent.</td>
<td></td>
</tr>
<tr>
<td>MVP Total RNA Human Adult Kidney</td>
<td></td>
</tr>
<tr>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td></td>
</tr>
</tbody>
</table>

1.3 Details of the supplier of the safety data sheet

Agilent Technologies Manufacturing GmbH & Co. KG
Hewlett-Packard-Str. 8
76337 Waldbronn
Germany
0800 603 1000
e-mail address of person responsible for this SDS: pdl-msds_author@agilent.com

1.4 Emergency telephone number

Emergency telephone number (with hours of operation): CHEMTREC®: +(44)-870-8200418

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition: MVP Total RNA Human Adult Kidney Mixture
MVP Total RNA, Human Adult Kidney Mixture
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]
Not classified.

See Section 16 for the full text of the H statements declared above.
See Section 11 for more detailed information on health effects and symptoms.

Date of issue/Date of revision: 29/12/2017
### SECTION 2: Hazards identification

| Signal word | : | MVP Total RNA Human Adult Kidney | No signal word. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | No signal word. |

| Hazard statements | : | MVP Total RNA Human Adult Kidney | No known significant effects or critical hazards. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | No known significant effects or critical hazards. |

| Precautionary statements |
| : | : |
| **Prevention** | : | MVP Total RNA Human Adult Kidney | Not applicable. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | Not applicable. |
| **Response** | : | MVP Total RNA Human Adult Kidney | Not applicable. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | Not applicable. |
| **Storage** | : | MVP Total RNA Human Adult Kidney | Not applicable. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | Not applicable. |
| **Disposal** | : | MVP Total RNA Human Adult Kidney | Not applicable. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | Not applicable. |

| Supplemental label elements | : | MVP Total RNA Human Adult Kidney | Not applicable. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | Not applicable. |

| Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles | : | MVP Total RNA Human Adult Kidney | Not applicable. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | Not applicable. |

| Special packaging requirements |
| : | : |
| **Tactile warning of danger** | : | MVP Total RNA Human Adult Kidney | Not applicable. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | Not applicable. |

| 2.3 Other hazards |
| : | : |
| **Other hazards which do not result in classification** | : | MVP Total RNA Human Adult Kidney | None known. |
| : | : | MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | None known. |
SECTION 3: Composition/information on ingredients

3.1 Substances

MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard
[2] Substance with a workplace exposure limit
[5] Substance of equivalent concern
[6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

Eye contact

MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.

Inhalation

MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.

Skin contact

MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.

Ingestion

MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

Protection of first-aiders

MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

No action shall be taken involving any personal risk or without suitable training.

4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effects
### SECTION 4: First aid measures

#### Eye contact
- **MVP Total RNA Human Adult Kidney**
  - No known significant effects or critical hazards.
- **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
  - No known significant effects or critical hazards.

#### Inhalation
- **MVP Total RNA Human Adult Kidney**
  - No known significant effects or critical hazards.
- **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
  - No known significant effects or critical hazards.

#### Skin contact
- **MVP Total RNA Human Adult Kidney**
  - No known significant effects or critical hazards.
- **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
  - No known significant effects or critical hazards.

#### Ingestion
- **MVP Total RNA Human Adult Kidney**
  - No known significant effects or critical hazards.
- **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
  - No known significant effects or critical hazards.

#### Over-exposure signs/symptoms

<table>
<thead>
<tr>
<th>Eye contact</th>
<th>Skin contact</th>
<th>Ingestion</th>
</tr>
</thead>
<tbody>
<tr>
<td>MVP Total RNA Human Adult Kidney</td>
<td>No specific data.</td>
<td>No specific data.</td>
</tr>
<tr>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No specific data.</td>
<td>No specific data.</td>
</tr>
<tr>
<td>MVP Total RNA Human Adult Kidney</td>
<td>No specific data.</td>
<td>No specific data.</td>
</tr>
<tr>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No specific data.</td>
<td>No specific data.</td>
</tr>
<tr>
<td>MVP Total RNA Human Adult Kidney</td>
<td>No specific data.</td>
<td>No specific data.</td>
</tr>
<tr>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No specific data.</td>
<td>No specific data.</td>
</tr>
</tbody>
</table>

#### 4.3 Indication of any immediate medical attention and special treatment needed

- **Notes to physician**
  - **MVP Total RNA Human Adult Kidney**
    - Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
  - **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
    - Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.

- **Specific treatments**
  - **MVP Total RNA Human Adult Kidney**
    - No specific treatment.
  - **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
    - No specific treatment.
SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media:
- MVP Total RNA Human Adult Kidney
- MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Use an extinguishing agent suitable for the surrounding fire.

Unsuitable extinguishing media:
- MVP Total RNA Human Adult Kidney
- MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

None known.

5.2 Special hazards arising from the substance or mixture

Hazardous combustion products:
- MVP Total RNA Human Adult Kidney
- MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

No specific data.

In a fire or if heated, a pressure increase will occur and the container may burst.

5.3 Advice for firefighters

Special precautions for fire-fighters:
- MVP Total RNA Human Adult Kidney
- MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.

Special protective equipment for fire-fighters:
- MVP Total RNA Human Adult Kidney
- MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel:
- MVP Total RNA Human Adult Kidney
- MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
SECTION 6: Accidental release measures

For emergency responders:
- **MVP Total RNA Human Adult Kidney**
  - If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

- **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
  - If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

**6.2 Environmental precautions**
- **MVP Total RNA Human Adult Kidney**
  - Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

- **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
  - Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

**6.3 Methods and material for containment and cleaning up**
- **Methods for cleaning up**
  - **MVP Total RNA Human Adult Kidney**
    - Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

  - **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
    - Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

**6.4 Reference to other sections**
- **See Section 1 for emergency contact information.**
- **See Section 8 for information on appropriate personal protective equipment.**
- **See Section 13 for additional waste treatment information.**

SECTION 7: Handling and storage

**7.1 Precautions for safe handling**
- **Protective measures**
  - **MVP Total RNA Human Adult Kidney**
    - Put on appropriate personal protective equipment (see Section 8).

  - **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
    - Put on appropriate personal protective equipment (see Section 8).

- **Advice on general occupational hygiene**
  - **MVP Total RNA Human Adult Kidney**
    - Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

  - **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
    - Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

**7.2 Conditions for safe storage, including any incompatibilities**
SECTION 7: Handling and storage

### Storage

**MVP Total RNA Human Adult Kidney**

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

**MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

### 7.3 Specific end use(s)

**Recommendations**

- **MVP Total RNA Human Adult Kidney**
  - Industrial applications.

- **MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma**
  - Industrial applications.

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

**Occupational exposure limits**

No exposure limit value known.

**Recommended monitoring procedures**

If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

**DNELs/DMELs**

No DNELs/DMELs available.

**PNECs**

No PNECs available

#### 8.2 Exposure controls

**Date of issue/Date of revision**

29/12/2017
SECTION 8: Exposure controls/personal protection

Appropriate engineering controls:

Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

Hygiene measures:

Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection:

Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection:

Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection:

Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection:

Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection:

Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Environmental exposure controls:

Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state:

MVP Total RNA Human Adult Kidney

MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Liquid.

MVP Total RNA Human Adult Kidney

MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Not available.

MVP Total RNA Human Adult Kidney

MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Not available.

MVP Total RNA Human Adult Kidney

MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Not available.

MVP Total RNA Human Adult Kidney

MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma

Not available.
# SECTION 9: Physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>pH</strong></td>
<td>MVP Total RNA Human Adult Kidney: 8</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: 8</td>
</tr>
<tr>
<td><strong>Melting point/freezing point</strong></td>
<td>MVP Total RNA Human Adult Kidney: 0°C</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: 0°C</td>
</tr>
<tr>
<td><strong>Initial boiling point and boiling range</strong></td>
<td>MVP Total RNA Human Adult Kidney: 100°C</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: 100°C</td>
</tr>
<tr>
<td><strong>Flash point</strong></td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Evaporation rate</strong></td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Flammability (solid, gas)</strong></td>
<td>Not applicable.</td>
</tr>
<tr>
<td><strong>Upper/lower flammability or explosive limits</strong></td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Vapour pressure</strong></td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Vapour density</strong></td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Relative density</strong></td>
<td>Not available.</td>
</tr>
<tr>
<td><strong>Solubility(ies)</strong></td>
<td>Easily soluble in the following materials: cold water and hot water.</td>
</tr>
<tr>
<td></td>
<td>Easily soluble in the following materials: cold water and hot water.</td>
</tr>
</tbody>
</table>

---

**Date of issue/Date of revision**: 29/12/2017
### SECTION 9: Physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Partition coefficient: n-octanol/water</strong></td>
<td>MVP Total RNA Human Adult Kidney: Not available.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: Not available.</td>
</tr>
<tr>
<td><strong>Auto-ignition temperature</strong></td>
<td>MVP Total RNA Human Adult Kidney: Not available.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: Not available.</td>
</tr>
<tr>
<td><strong>Decomposition temperature</strong></td>
<td>MVP Total RNA Human Adult Kidney: Not available.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: Not available.</td>
</tr>
<tr>
<td><strong>Viscosity</strong></td>
<td>MVP Total RNA Human Adult Kidney: Not available.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: Not available.</td>
</tr>
<tr>
<td><strong>Explosive properties</strong></td>
<td>MVP Total RNA Human Adult Kidney: Not available.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: Not available.</td>
</tr>
<tr>
<td><strong>Oxidising properties</strong></td>
<td>MVP Total RNA Human Adult Kidney: Not available.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: Not available.</td>
</tr>
</tbody>
</table>

**9.2 Other information**

No additional information.

### SECTION 10: Stability and reactivity

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>10.1 Reactivity</strong></td>
<td>MVP Total RNA Human Adult Kidney: No specific test data related to reactivity available.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: No specific test data related to reactivity available.</td>
</tr>
<tr>
<td><strong>10.2 Chemical stability</strong></td>
<td>MVP Total RNA Human Adult Kidney: The product is stable.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: The product is stable.</td>
</tr>
<tr>
<td><strong>10.3 Possibility of hazardous reactions</strong></td>
<td>MVP Total RNA Human Adult Kidney: Under normal conditions of storage and use, hazardous reactions will not occur.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: Under normal conditions of storage and use, hazardous reactions will not occur.</td>
</tr>
<tr>
<td><strong>10.4 Conditions to avoid</strong></td>
<td>MVP Total RNA Human Adult Kidney: No specific data.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: No specific data.</td>
</tr>
</tbody>
</table>

**Date of issue/Date of revision**: 29/12/2017
SECTION 10: Stability and reactivity

10.5 Incompatible materials

MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma
May react or be incompatible with oxidising materials.

10.6 Hazardous decomposition products

MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma
Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity
Not available.

Acute toxicity estimates
Not available.

Irritation/Corrosion
Conclusion/Summary : Not available.

Sensitiser
Conclusion/Summary : Not available.

Specific target organ toxicity (single exposure)
Not available.

Specific target organ toxicity (repeated exposure)
Not available.

Aspiration hazard
Not available.

Information on likely routes of exposure
MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma
Not available.

Potential acute health effects

Inhalation
MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma
No known significant effects or critical hazards.

Ingestion
MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma
No known significant effects or critical hazards.

Skin contact
MVP Total RNA Human Adult Kidney
MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma
No known significant effects or critical hazards.

Date of issue/Date of revision : 29/12/2017
### SECTION 11: Toxicological information

#### Potential chronic health effects

<table>
<thead>
<tr>
<th>Eye contact</th>
<th>MVP Total RNA Human Adult Kidney</th>
<th>No known significant effects or critical hazards.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No known significant effects or critical hazards.</td>
</tr>
</tbody>
</table>

#### Symptoms related to the physical, chemical and toxicological characteristics

<table>
<thead>
<tr>
<th>Inhalation</th>
<th>MVP Total RNA Human Adult Kidney</th>
<th>No specific data.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No specific data.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingestion</th>
<th>MVP Total RNA Human Adult Kidney</th>
<th>No specific data.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No specific data.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Skin contact</th>
<th>MVP Total RNA Human Adult Kidney</th>
<th>No specific data.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No specific data.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Eye contact</th>
<th>MVP Total RNA Human Adult Kidney</th>
<th>No specific data.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No specific data.</td>
</tr>
</tbody>
</table>

#### Delayed and immediate effects as well as chronic effects from short and long-term exposure

**Short term exposure**

- **Potential immediate effects**: Not available.
- **Potential delayed effects**: Not available.

**Long term exposure**

- **Potential immediate effects**: Not available.
- **Potential delayed effects**: Not available.

#### Potential chronic health effects

**General**

- MVP Total RNA Human Adult Kidney | No known significant effects or critical hazards. |
- MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | No known significant effects or critical hazards. |

**Carcinogenicity**

- MVP Total RNA Human Adult Kidney | No known significant effects or critical hazards. |
- MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | No known significant effects or critical hazards. |

**Mutagenicity**

- MVP Total RNA Human Adult Kidney | No known significant effects or critical hazards. |
- MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma | No known significant effects or critical hazards. |
SECTION 11: Toxicological information

<table>
<thead>
<tr>
<th>Category</th>
<th>Substance Description</th>
<th>Toxicological Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teratogenicity</td>
<td>MVP Total RNA Human Adult Kidney</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td>Developmental effects</td>
<td>MVP Total RNA Human Adult Kidney</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td>Fertility effects</td>
<td>MVP Total RNA Human Adult Kidney</td>
<td>No known significant effects or critical hazards.</td>
</tr>
<tr>
<td></td>
<td>MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma</td>
<td>No known significant effects or critical hazards.</td>
</tr>
</tbody>
</table>

SECTION 12: Ecological information

12.1 Toxicity

Conclusion/Summary: Not available.

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition coefficient (K_{oc}): Not available.

Mobility: Not available.

12.5 Results of PBT and vPvB assessment

PBT: Not applicable.

vPvB: Not applicable.

12.6 Other adverse effects: No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

Methods of disposal: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste: Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

Packaging

Methods of disposal: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Date of issue/Date of revision: 29/12/2017
SECTION 13: Disposal considerations

Special precautions: This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spill material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

ADR/RID / IMDG / IATA: Not regulated.

14.6 Special precautions for user: Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code: Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

MVP Total RNA Human Adult Kidney: Not applicable.

MVP Total RNA, Human Adult Kidney, Renal Cell Carcinoma: Not applicable.

Other EU regulations

Ozone depleting substances (1005/2009/EU)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Seveso Directive

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol (Annexes A, B, C, E)

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNEP Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Date of issue/Date of revision: 29/12/2017
SECTION 15: Regulatory information

Australia: All components are listed or exempted.
Canada: All components are listed or exempted.
China: All components are listed or exempted.
Europe: All components are listed or exempted.
Japan:
  - Japan inventory (ENCS): All components are listed or exempted.
  - Japan inventory (ISHL): All components are listed or exempted.
Malaysia: Not determined.
New Zealand: All components are listed or exempted.
Philippines: All components are listed or exempted.
Republic of Korea: All components are listed or exempted.
Taiwan: All components are listed or exempted.
Thailand: Not determined.
Turkey: Not determined.
United States: All components are listed or exempted.
Viet Nam: Not determined.

15.2 Chemical safety assessment: This product contains substances for which Chemical Safety Assessments might still be required.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms:
ATE = Acute Toxicity Estimate
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]
DNEL = Derived No Effect Level
EUH statement = CLP-specific Hazard statement
PNEC = Predicted No Effect Concentration
RRN = REACH Registration Number

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

<table>
<thead>
<tr>
<th>Classification</th>
<th>Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not classified.</td>
<td></td>
</tr>
</tbody>
</table>

Full text of abbreviated H statements
Not applicable.

Full text of classifications [CLP/GHS]
Not applicable.

Date of issue/ Date of revision: 29/12/2017
Date of previous issue: No previous validation.
Version: 1

Notice to reader

Disclaimer: The information contained in this document is based on Agilent’s state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.